$71.1
+3.2
(+4.71%)▲
Insights on Axsome Therapeutics, Inc.
Revenue is up for the last 3 quarters, 46.7M → 71.53M (in $), with an average increase of 19.2% per quarter
Netprofit is down for the last 2 quarters, -62.19M → -98.65M (in $), with an average decrease of 58.6% per quarter
In the last 1 year, Novo Nordisk A/s has given 45.1% return, outperforming this stock by 47.6%
In the last 3 years, Novo Nordisk A/s has given 238.3% return, outperforming this stock by 203.9%
5.36%
Downside
Day's Volatility :5.62%
Upside
0.28%
22.62%
Downside
52 Weeks Volatility :44.09%
Upside
27.74%
Period | Axsome Therapeutics, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -20.58% | -0.4% | 0.0% |
6 Months | 14.66% | 9.6% | 0.0% |
1 Year | -3.03% | 3.9% | -1.3% |
3 Years | 34.43% | 12.8% | -22.1% |
Market Capitalization | 3.2B |
Book Value | $4.03 |
Earnings Per Share (EPS) | -5.27 |
PEG Ratio | 0.0 |
Wall Street Target Price | 123.0 |
Profit Margin | -88.41% |
Operating Margin TTM | -77.68% |
Return On Assets TTM | -24.86% |
Return On Equity TTM | -159.21% |
Revenue TTM | 270.6M |
Revenue Per Share TTM | 5.96 |
Quarterly Revenue Growth YOY | 193.5% |
Gross Profit TTM | 45.9M |
EBITDA | -182.4M |
Diluted Eps TTM | -5.27 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.77 |
EPS Estimate Next Year | 1.13 |
EPS Estimate Current Quarter | -1.17 |
EPS Estimate Next Quarter | -1.1 |
What analysts predicted
Upside of 73.0%
Sell
Neutral
Buy
Axsome Therapeutics, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Axsome Therapeutics, Inc. | -8.08% | 14.66% | -3.03% | 34.43% | 346.05% |
Moderna, Inc. | -5.36% | 32.83% | -24.38% | -39.84% | 322.91% |
Regeneron Pharmaceuticals, Inc. | -6.34% | 13.15% | 12.94% | 84.22% | 161.57% |
Novo Nordisk A/s | -2.94% | 28.97% | 46.95% | 238.27% | 414.84% |
Vertex Pharmaceuticals Incorporated | -3.87% | 8.77% | 20.15% | 83.53% | 128.04% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Axsome Therapeutics, Inc. | NA | NA | 0.0 | -3.77 | -1.59 | -0.25 | NA | 4.03 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.77 | 25.77 | 1.46 | 45.22 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.13 | 46.13 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.39 | 28.39 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Axsome Therapeutics, Inc. | Buy | $3.2B | 346.05% | NA | -88.41% |
Moderna, Inc. | Buy | $38.8B | 322.91% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.4B | 161.57% | 25.77 | 30.14% |
Novo Nordisk A/s | Buy | $551.3B | 414.84% | 46.13 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 128.04% | 28.39 | 36.68% |
RTW INVESTMENTS, LLC
Vanguard Group Inc
BlackRock Inc
Fairmount Funds Management LLC
Bvf Inc
Citadel Advisors Llc
Axsome Therapeutics, Inc.’s price-to-earnings ratio stands at None
Read Moreaxsome therapeutics is a biopharmaceutical company developing novel therapies for the treatment of cns disorders. axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. the company is based in new york city.
Organization | Axsome Therapeutics, Inc. |
Employees | 545 |
CEO | Dr. Herriot Tabuteau M.D. |
Industry | Health Technology |
Cg Oncology Inc.
$71.10
+4.71%
Taiwan Msci Etf Ishares
$71.10
+4.71%
Sl Green Realty Corp.
$71.10
+4.71%
Lg Display Co., Ltd.
$71.10
+4.71%
Willscot Mobile Mini Holding
$71.10
+4.71%
Nnn Reit Inc.
$71.10
+4.71%
Cerevel Therapeutics Holdings Inc
$71.10
+4.71%
Spdr S&p 400 Mid Cap Value E
$71.10
+4.71%
Vanguard Russell 1000 Etf
$71.10
+4.71%